As with any therapeutic, the design of the manufacturing process is central in being able to efficiently produce, and provide patients with, quality treatments. For cell and gene therapies (CGTs), however, the challenges in optimizing this process are unique due to the complex nature of the technology which is ever evolving and means dealing with high degrees of variability.
It’s a topic which is comprised of a few recurring debates that can often polarize industry experts into different camps....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?